Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| mRNA Expression and Methylation of the RAD51, ATM, ATR, BRCA1, and BRCA2 Genes in Gastric Adenocarcinoma. | Biomark Insights | 2024 | 38293680 | PubTator, text mining | PubMed |
| The role of aberrant DNA methylation in cancer initiation and clinical impacts. | Ther Adv Med Oncol | 2024 | 38293277 | PubTator, text mining | PubMed |
| Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets. | Int J Mol Sci | 2024 | 38279263 | PubTator, text mining | PubMed |
| Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. | Hum Pathol | 2024 | 38278448 | PubTator, text mining | PubMed |
| Research progress in intratumoral heterogeneity and clinical significance of ovarian cancer. | Medicine (Baltimore) | 2024 | 38277565 | PubTator, text mining | PubMed |
| High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive. | Biomedicines | 2024 | 38275400 | PubTator, text mining | PubMed |
| The Role of Key Amino Acids of the Human Fe(II)/2OG-Dependent Dioxygenase ALKBH3 in Structural Dynamics and Repair Activity toward Methylated DNA. | Int J Mol Sci | 2024 | 38256217 | PubTator, text mining | PubMed |
| Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research. | Int J Mol Sci | 2024 | 38256166 | PubTator, text mining | PubMed |
| Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro. | Int J Mol Sci | 2024 | 38255960 | PubTator, text mining | PubMed |
| How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update. | Cancers (Basel) | 2024 | 38254807 | PubTator, text mining | PubMed |
| Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer? | Cancers (Basel) | 2024 | 38254803 | PubTator, text mining | PubMed |
| Established and Evolving Roles of the Multifunctional Non-POU Domain-Containing Octamer-Binding Protein (NonO) and Splicing Factor Proline- and Glutamine-Rich (SFPQ). | J Dev Biol | 2024 | 38248868 | PubTator, text mining | PubMed |
| The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme. | Cells | 2024 | 38247816 | PubTator, text mining | PubMed |
| Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer. | Case Rep Oncol Med | 2024 | 38239272 | PubTator, text mining | PubMed |
| ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. | Oncotarget | 2024 | 38227740 | PubTator, text mining | PubMed |
| BRCA2, PALB2, RECQL4 Germline Pathogenic Variants, and Somatic TP53 Mutation in Triple Metachronous Malignancies: A Case Report and Literature Review. | Int Med Case Rep J | 2024 | 38223534 | PubTator, text mining | PubMed |
| Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing. | Pathol Res Pract | 2024 | 38219492 | PubTator, text mining | PubMed |
| Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. | Genome Med | 2024 | 38217005 | PubTator, text mining | PubMed |
| Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions. | J Cancer | 2024 | 38213724 | PubTator, text mining | PubMed |
| Development of PARP inhibitors in advanced prostate cancer. | Ther Adv Med Oncol | 2024 | 38205078 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=12